Sruthi Sritharan

511 total citations · 1 hit paper
7 papers, 358 citations indexed

About

Sruthi Sritharan is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Biomaterials. According to data from OpenAlex, Sruthi Sritharan has authored 7 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Cardiology and Cardiovascular Medicine and 3 papers in Biomaterials. Recurrent topics in Sruthi Sritharan's work include Nanoparticle-Based Drug Delivery (3 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers) and Cancer-related cognitive impairment studies (2 papers). Sruthi Sritharan is often cited by papers focused on Nanoparticle-Based Drug Delivery (3 papers), Chemotherapy-induced cardiotoxicity and mitigation (3 papers) and Cancer-related cognitive impairment studies (2 papers). Sruthi Sritharan collaborates with scholars based in India. Sruthi Sritharan's co-authors include N Sivalingam and has published in prestigious journals such as Life Sciences, Archives of Toxicology and APOPTOSIS.

In The Last Decade

Sruthi Sritharan

7 papers receiving 355 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A comprehensive review on time-tested anticancer drug doxorubicin

2021 310 citations Sruthi Sritharan, N Sivalingam Life Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sruthi Sritharan India	4	149	82	80	67	54	7	358
Hamed Bagheri Iran	10	126 0.8×	119 1.5×	113 1.4×	57 0.9×	24 0.4×	34	464
Jing Xia China	11	276 1.9×	99 1.2×	44 0.6×	107 1.6×	106 2.0×	30	552
Francisca E. Cara Spain	11	159 1.1×	64 0.8×	66 0.8×	70 1.0×	20 0.4×	15	387
Tanaya R. Vaidya United States	7	158 1.1×	63 0.8×	53 0.7×	135 2.0×	214 4.0×	17	439
Juan Zhao China	14	127 0.9×	74 0.9×	80 1.0×	70 1.0×	11 0.2×	32	402
Zhongcheng Ke China	10	213 1.4×	117 1.4×	42 0.5×	55 0.8×	17 0.3×	26	486
Marzena Szwed Poland	15	267 1.8×	192 2.3×	138 1.7×	145 2.2×	45 0.8×	41	643
Luyu Qi China	6	153 1.0×	42 0.5×	37 0.5×	138 2.1×	18 0.3×	10	407
Xinran Cao China	13	132 0.9×	31 0.4×	86 1.1×	27 0.4×	68 1.3×	41	448
Yongji Li China	15	207 1.4×	152 1.9×	99 1.2×	43 0.6×	10 0.2×	38	591

Countries citing papers authored by Sruthi Sritharan

Since Specialization

Citations

This map shows the geographic impact of Sruthi Sritharan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sruthi Sritharan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sruthi Sritharan more than expected).

Fields of papers citing papers by Sruthi Sritharan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sruthi Sritharan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sruthi Sritharan. The network helps show where Sruthi Sritharan may publish in the future.

Co-authorship network of co-authors of Sruthi Sritharan

This figure shows the co-authorship network connecting the top 25 collaborators of Sruthi Sritharan. A scholar is included among the top collaborators of Sruthi Sritharan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sruthi Sritharan. Sruthi Sritharan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Sritharan, Sruthi & N Sivalingam. (2025). A recent decade update on combating doxorubicin-induced toxicities. Archives of Toxicology. 99(9). 3565–3578. 1 indexed citations

2.

Sritharan, Sruthi & N Sivalingam. (2024). Secretion of IL-6 and TGF-β2 by Colon Cancer Cells May Promote Resistance to Chemotherapy. Indian Journal of Clinical Biochemistry. 41(2). 259–266. 1 indexed citations

3.

Sritharan, Sruthi & N Sivalingam. (2024). Doxorubicin-induced chemoresistance in Duke’s type B colon adenocarcinoma cell line is aggravated in the presence of TGF-β2 through non-apoptotic cell death. Clinical & Translational Oncology. 26(7). 1630–1638. 1 indexed citations

4.

Sritharan, Sruthi, et al.. (2022). Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance. APOPTOSIS. 27(9-10). 622–646. 9 indexed citations

5.

Sritharan, Sruthi & N Sivalingam. (2021). A comprehensive review on time-tested anticancer drug doxorubicin. Life Sciences. 278. 119527–119527. 310 indexed citations breakdown →

6.

Sritharan, Sruthi, et al.. (2020). Curcumin induces chemosensitization to doxorubicin in Duke’s type B coloadenocarcinoma cell line. Molecular Biology Reports. 47(10). 7883–7892. 13 indexed citations

7.

Sritharan, Sruthi & N Sivalingam. (2020). Curcumin induced apoptosis is mediated through oxidative stress in mutated p53 and wild type p53 colon adenocarcinoma cell lines. Journal of Biochemical and Molecular Toxicology. 35(1). e22616–e22616. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact